Patients with Crohn's disease who show an initial response to a single dose of infliximab (Remicade) are more likely to remain in remission a year later if therapy is maintained every 8 weeks, say these researchers.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Infliximab could provide new long-term option for Crohn's disease

Newsletter